ISOLATION AND EXPRESSION OF COCCIDIOIDES T CELL ANTIGENS
球孢子菌 T 细胞抗原的分离和表达
基本信息
- 批准号:6657468
- 负责人:
- 金额:$ 15.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-01 至 2003-07-31
- 项目状态:已结题
- 来源:
- 关键词:Coccidioides immitis T lymphocyte beta glucosidases cellular immunity coccidioidomycosis disease /disorder model epitope mapping fungal antigens fungal proteins fungal vaccines gene expression glycoproteins laboratory mouse leukocyte activation /transformation recombinant proteins serine proteinases urease vaccine development
项目摘要
Coccidioidomycosis is a disease in which T-cell mediated immunity has been
shown to play a critical role in host defense. Both clinical and
experimental data support this conclusion. An unusual feature of this
mycosis is that high titers of antibody, as detected by complement
fixation, are a poor prognostic sign. Therefore, determination of which C.
immitis antigens stimulate T-cell responses rather than antibody responses
is essential for subsequent isolation of macromolecules of the organism
that elicit immunoprotection. In the proposed research, we have used a
novel molecular approach to the systematic identification of the
recombinant T-cell reactive proteins (RTPs), an evaluation of the
immunoprotective properties of these macromolecules in a murine model of
coccidioidomycosis. Results of our earlier studies have indicated that
potent T-cell reactive proteins are expressed during 1) transition of the
saprobic to parasitic phase, 2) isotropic growth of spherules, and 3)
endosporulation. On this basis, we will construct three corresponding cDNA
expression libraries with mRNA isolated from the above parasitic phases.
The libraries will be screened with existing antiserum raised against cell
wall and whole cell preparations which have been shown to be T-cell
reactive in immune lymph node proliferation (ILNP) assays. Reactive clones
are isolated and the C. immitis cDNA of each is ligated into the pCMV
mammalian expression vector. BALB/c mice are immunized subcutaneously with
the pCMV plus cDNA insert which expresses the C. immitis protein. Mice are
monitored by ELISA for production of the antibody against crude C. immitis
antigen and then sacrificed for evaluation of their T-cell reactivity in
ILNP assays. The cDNA of reactive clones is subcloned into a prokaryotic
expression vector (e.g., pSE40), and the RTP is purified by immunoaffinity
chromatography using the corresponding specific murine antiserum obtained
as sacrifice, as above. The RTP is further tested for reactivity in murine
ILNP assays and T-cell lines, an in patient lymphocyte proliferation
assays. The selected cDNAs are used to screen the original expression
library, or a C. immitis genomic library, to isolate the full-length gene.
The cDNA from that gene will be used for expression o the RTP for further
evaluation of its reactivity as above. Ultimately, this approach will
yield multiple RTPs which can be evaluated for immunoprotection in mice
against C. immitis challenge. Immunoprotective recombinant proteins
obtained by this approach are qualified candidates for a human vaccine
against coccidioidomycosis.
球孢子菌病是一种T细胞介导的免疫系统被破坏的疾病。
在宿主防御中起着关键作用。 临床和
实验数据支持这一结论。 这其中一个不寻常的特点是
真菌病是由补体检测到最高滴度抗体
固视是预后不良的标志。 因此,确定哪种C.
免疫性抗原刺激T细胞应答而不是抗体应答
是随后分离生物体大分子所必需的
引发免疫保护。 在拟议的研究中,我们使用了
一种新的分子方法来系统地鉴定
重组T细胞反应蛋白(RTPs),
这些大分子在小鼠模型中的免疫保护特性
球孢子菌病 我们早期的研究结果表明,
有效的T细胞反应蛋白在以下过程中表达:1)
腐殖到寄生阶段,2)小球的各向同性生长,以及3)
内孢子形成 在此基础上,我们将构建三个相应的cDNA,
用从上述寄生阶段分离的mRNA构建表达文库。
将用针对细胞的现有抗血清筛选文库。
已被证明是T细胞的壁和全细胞制剂
在免疫淋巴结增殖(ILNP)测定中具有反应性。 反应性克隆
分离得到C.将每一种的猴cDNA连接到pCMV中,
哺乳动物表达载体。 BALB/c小鼠皮下免疫
表达C.免疫蛋白。 小鼠
通过ELISA监测针对粗C.丝虫
抗原,然后处死以评估它们在
ILNP测定。 将反应性克隆的cDNA亚克隆到原核生物中,
表达载体(例如,pSE 40),并通过免疫亲和纯化RTP
使用获得的相应的特异性鼠抗血清进行层析,
作为牺牲,如上所述。 在鼠中进一步测试RTP的反应性。
ILNP测定和T细胞系,患者淋巴细胞增殖
分析。 筛选出的cDNA用于筛选原始表达
图书馆或C。immitis基因组文库,分离全长基因。
来自该基因的cDNA将用于RTP的表达,用于进一步的研究。
如上所述评价其反应性。 最终,这种方法将
产生多个RTP,其可用于评价小鼠的免疫保护
针对C.免疫激发。 免疫保护性重组蛋白
通过这种方法获得的是人用疫苗的合格候选物
对抗球孢子菌病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARRY Thomas COLE其他文献
GARRY Thomas COLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARRY Thomas COLE', 18)}}的其他基金
A Recombinant Protein Vaccine Against Coccidioidomycosis
一种抗球孢子菌病的重组蛋白疫苗
- 批准号:
8082225 - 财政年份:2010
- 资助金额:
$ 15.71万 - 项目类别:
A Recombinant Protein Vaccine Against Coccidioidomycosis
一种抗球孢子菌病的重组蛋白疫苗
- 批准号:
7577430 - 财政年份:2008
- 资助金额:
$ 15.71万 - 项目类别:
A Recombinant Protein Vaccine Against Coccidioidomycosis
一种抗球孢子菌病的重组蛋白疫苗
- 批准号:
8019458 - 财政年份:2008
- 资助金额:
$ 15.71万 - 项目类别:
A Recombinant Protein Vaccine Against Coccidioidomycosis
一种抗球孢子菌病的重组蛋白疫苗
- 批准号:
8231410 - 财政年份:2008
- 资助金额:
$ 15.71万 - 项目类别:
A Recombinant Protein Vaccine Against Coccidioidomycosis
一种抗球孢子菌病的重组蛋白疫苗
- 批准号:
7463462 - 财政年份:2008
- 资助金额:
$ 15.71万 - 项目类别:
A Recombinant Protein Vaccine Against Coccidioidomycosis
一种抗球孢子菌病的重组蛋白疫苗
- 批准号:
7775116 - 财政年份:2008
- 资助金额:
$ 15.71万 - 项目类别:
ISOLATION AND EXPRESSION OF COCCIDIOIDES T CELL ANTIGENS
球孢子菌 T 细胞抗原的分离和表达
- 批准号:
6493571 - 财政年份:2001
- 资助金额:
$ 15.71万 - 项目类别:
ISOLATION AND EXPRESSION OF COCCIDIOIDES T CELL ANTIGENS
球孢子菌 T 细胞抗原的分离和表达
- 批准号:
6347211 - 财政年份:2000
- 资助金额:
$ 15.71万 - 项目类别:
ISOLATION AND EXPRESSION OF COCCIDIOIDES T CELL ANTIGENS
球孢子菌 T 细胞抗原的分离和表达
- 批准号:
6344624 - 财政年份:2000
- 资助金额:
$ 15.71万 - 项目类别:
ISOLATION AND EXPRESSION OF COCCIDIOIDES T CELL ANTIGENS
球孢子菌 T 细胞抗原的分离和表达
- 批准号:
6218779 - 财政年份:1999
- 资助金额:
$ 15.71万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 15.71万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 15.71万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 15.71万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 15.71万 - 项目类别:
Discovery Grants Program - Individual